GWPH Overview
Upcoming Projects (GWPH)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (GWPH)
-
Don’t see a project related to the company you care about? Create your own!
Expired Projects (GWPH)
-
Now that Zogenix's FINTEPLA is approved by the FDA, how does the label impact the commercial prospects of the drug?
Tickers: ZGNX, GWPH
Execute By: Aug 07, 2020
Upcoming & Overdue Catalysts (GWPH)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (GWPH)
-
FDA Approves EPIDIOLEX (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex
Ticker: GWPH
Occurred on: Aug 03, 2020 -
Phase 3 GWPCARE2 data of GW Pharmaceuticals'(GWPH) Epidiolex in Dravet Syndrome to be presented at AAN May 7, 2019
Ticker: GWPH
Occurred on: May 07, 2019 -
Data from Part B of GW Pharma's (GWPH) Phase 2 Study Evaluating CBDV (GWP42006) in Partial-Onset Epilepsy due H1 2017
Ticker: GWPH
Occurred on: Feb 21, 2018 -
GW Pharma (GWPH) to Initiate Phase 2 Placebo-Controlled Study in H2 2017 Evaluating CBDV (GWP42006) in Autism Spectrum Disorders
Ticker: GWPH
Occurred on: Feb 21, 2018 -
GW Pharma (GWPH) Expects to Submit European Union Marketing Application in H2 for Epidiolex in Lennox-Gastaut Syndrome
Ticker: GWPH
Occurred on: Dec 29, 2017 -
GW Pharma (GWPH) Expects to Submit European Union Marketing Application in H2 for Epidiolex in Dravet Syndrome
Ticker: GWPH
Occurred on: Dec 29, 2017 -
GW Pharma (GWPH) Expects to Submit New Drug Application to FDA Mid-Year for Epidiolex in Lennox-Gastaut Syndrome
Ticker: GWPH
Occurred on: Aug 07, 2017 -
GW Pharma (GWPH) Expects to Submit New Drug Application to FDA Mid-Year for Epidiolex in Dravet Syndrome
Ticker: GWPH
Occurred on: Aug 07, 2017 -
GW Pharma (GWPH) to File New Drug Application (NDA) for Epidiolex in Dravet Syndrome and Lennox-Gastaut-Syndrome (LGS) in H1 of 2017
Ticker: GWPH
Occurred on: Aug 07, 2017 -
Zogenix (ZGNX) Expects Results From Phase 3 Study 1502 Evaluating ZX008 in Dravet Syndrome in Q1 2017
Tickers: ZGNX, GWPH
Occurred on: May 25, 2017 -
GW Pharma's (GWPH) Phase 2 Data Evaluating Sativex in Children with Spasticity due to Cerebral Palsy Expected in Q1 2017
Ticker: GWPH
Occurred on: May 16, 2017 -
GW Pharma (GWPH) to Initiate Phase 3 Trial Evaluating Epidiolex in Infantile Spasms (IS) in Q4 2016
Ticker: GWPH
Occurred on: Mar 17, 2017 -
GW Pharma (GWPH) Phase 1b/2a Study Evaluating THC:CBD in Treatment of Recurrent Glioblastoma Multiforme (GBM)
Ticker: GWPH
Occurred on: Feb 07, 2017 -
GW Pharma (GWPH) to Commence Early Open-Label Clinical Trial in H2 2016 Evaluating CBDV (GWP42006) in Autism Spectrum Disorders
Ticker: GWPH
Occurred on: Dec 05, 2016 -
Zogenix (ZGNX) Expects Phase 3 Study 1501 data for ZX008 in Dravet Syndrome in Late 2016
Tickers: ZGNX, GWPH
Occurred on: Dec 05, 2016 -
GW Pharma (GWPH) Expects to Present Phase 3 Data on Epidiolex at American Epilepsy Society Annual Meeting December 2-6
Tickers: GWPH, ZGNX
Occurred on: Dec 05, 2016 -
Phase 3 Data from Second Epidiolex Lennox-Gastaut Syndrome Study due H2 2016
Ticker: GWPH
Occurred on: Sep 26, 2016 -
GW Pharma (GWPH) Phase 3 Data from Two Lennox-Gastaut Syndrome Studies of Epidiolex Due mid-2016
Ticker: GWPH
Occurred on: Jun 27, 2016 -
GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS)
Ticker: GWPH
Occurred on: Jun 21, 2016 -
GW Pharmaceuticals Receives Orphan Drug Designation from FDA for Cannabidiol for the Treatment of Tuberous Sclerosis Complex
Ticker: GWPH
Occurred on: Apr 21, 2016 -
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
Ticker: GWPH
Occurred on: Apr 11, 2016 -
GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex (cannabidiol)
Ticker: GWPH
Occurred on: Mar 14, 2016 -
Top line Phase 3 data of Epidiolex for Dravet Syndrome expected 1Q 2016 (first trial)
Ticker: GWPH
Occurred on: Mar 14, 2016
Strategic Initiatives (GWPH)
-
Jazz (Jazz) to acquire GW Pharmaceuticals (GWPH) for $7.2 billion
Tickers: JAZZ, GWPH
Announcement Date: Feb 03, 2021
